You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新華製藥(000756.SZ)與中國藥科大學達成戰略合作
格隆匯 03-26 16:49

格隆匯3月26日丨新華製藥(000756.SZ)宣佈,2021年3月24日,公司作為甲方與中國藥科大學作為乙方簽訂了“重大創新藥物和高端製劑聯合研究開發合作協議”。

合作目的和目標:甲乙雙方以甲方選定的創新藥物和改良型新藥3個項目為載體,完成3個創新藥物和改良型新藥項目的臨牀轉化,協助甲方取得3個項目的新藥生產批件;探索創新藥物(包含但不限於小分子化學藥物、大分子生物藥物、重大疾病治療技術等)合作。加快推進“中國藥科大學--新華製藥創新藥物及高端製劑聯合研究中心”,“新華製藥-中國藥科大學重大公共安全及應急用藥研發創新中心”2箇中心建設(“兩個中心”),實現甲方創新藥物和高端製劑的產業化,並以此為契機,通過項目合作完善甲方人才隊伍建設,培養一批創新藥和高端製劑開發方面的專業化人才。

該協議以創新藥物和改良型新藥3個項目為依託,甲方向乙方提供項目研究費用,總經費合計為人民幣3000萬元整,按照合同約定分期支付給乙方。產品取得生產批件上市之日起的5年內,甲方按產品實際銷售額向乙方支付銷售分成,分成比例按當年實際銷售金額的2%支付。

公司表示,公司與中國藥科大學此次項目合作是一次戰略合作。中國藥科大學在該領域的研究水平處於國內領先地位,在創新藥、高端製劑、改良型新藥等方面具有優勢,為公司提供製劑技術創新的關鍵理論、人才培養及技術服務;協助公司開展“中國藥科大學--新華製藥創新藥物及高端製劑聯合研究中心”及“新華製藥-中國藥科大學重大公共安全及應急用藥研發創新中心”建設,在創新藥立項、法規政策諮詢等方面提供技術指導。雙方在院士工作站、博士後工作站、研究生聯合培養、實訓實踐基地的建設上,建立長效合作機制,形成學術與人才互動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account